LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (the “ Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce it has engaged Kanan Corbin Schupak & Aronow, Inc. d/b/a KCSA Strategic Communications (“KCSA”) to provide investor relations and public relations services (the “Services”). KCSA has agreed to…

Source

Previous articleatai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data
Next articleUnderstanding ‘Spiritual Emergency’ in the Context of Psychedelics